Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; KYNMOBI a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. (($AQST)) has held its Q2 earnings call. Read on for the main highlights of the call. Aquestive Therapeutics’ latest e...

Aquestive Therapeutics Earnings Call Highlights Anaphylm Progress

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Heron Therapeutics (HRTX), Aquestive Therapeutics (AQST) and Axso...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AQST	$5.34	-0.19%	2.12M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AQST	$5.34	-0.2%	2.12M
3
4
5
6

AQST

Get Aquestive Therapeutics, Inc. Data in Excel

Get Aquestive Therapeutics, Inc. Data in Excel